Press Releases for ALXA

Press Releases
Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro
Alexza Reports 2009 Second Quarter Financial Results and Updates Clinical Pipeline Status
Alexza to Announce 2009 Second Quarter Financial Results and Update Its Clinical Pipeline Status on Wednesday, August 5, 2009
Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002
Alexza's Corporate Presentation to be Webcast at the Piper Jaffray Fourth Annual Europe Conference
Alexza's Corporate Presentation to be Webcast at the Eighth Annual JMP Securities Research Conference
Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
Alexza to Announce 2009 First Quarter Financial Results and Update Its Clinical Pipeline Status on Thursday, May 7, 2009
Alexza's Corporate Presentation to be Webcast at the Future Leaders in the Biotech Industry Conference
Alexza Reports 2008 Year-End Financial Results and Updates Clinical Pipeline Status
Alexza's Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference
Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009
Migraine Therapeutics Reviewed by NeuroInvestment
Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D
Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference
Schizophrenia Therapeutics Reviewed by NeuroInvestment
Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
/C O R R E C T I O N -- Alexza Pharmaceuticals, Inc./
Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts
Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates
Alexza to Announce 2008 Third Quarter Financial Results and Update Its Clinical Pipeline on Thursday, November 6, 2008
Alexza Completes Enrollment in Second Phase 3 Clinical Trial With AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Alexza's Corporate Presentation to be Webcast at the Third Annual JMP Securities Healthcare Focus
Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday, August 6, 2008
Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
Alexza's Corporate Presentation to be Webcast at the Piper Jaffray Third Annual Europe Conference
Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. - May 27 2008 12:57AM
Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality - May 27 2008 12:55AM
Alexza's Corporate Presentation to be Webcast at the Seventh Annual JMP Securities Research Conference and the 2008 Citi Investment Research Global Healthcare Conference - May 27 2008 12:53AM
Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates - Jun 1 2008 7:07AM
Alexza to Announce 2008 First Quarter Financial Results and Update Its Clinical Pipeline on Monday, May 12, 2008 - Jun 1 2008 7:06AM
Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting - Jun 1 2008 7:06AM
Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
Alexza's Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Unplugged Conference
Alexza to Webcast Investor and Analyst Day Presentations